BioCardia, Inc. (NASDAQ: BCDA) shares has increased significantly this morning since the company received recent regulatory approval. As of the most recent update, BCDA stock was trading at $3.57 with a 62.27% rise.
This increase follows the company’s press release stating that the FDA in the United States has given the business permission to commercialize its Morph DNA Steerable Introducer product family in accordance with the Federal Food, Drug, and Cosmetic Act’s general regulations.
FDA Clears New Product Line for Market
With FDA approval, the Morph DNA Steerable Introducer product line makes it easier to insert different medical devices into the heart chambers or peripheral vasculature, including guidewires, balloon dilatation catheters, and other therapeutic devices.
The 16 distinct goods covered by the clearance have diameters that correspond to French introducer sheaths 5, 6, 7, and 8, and lengths that range from 30 to 90 centimeters. These products are expected to cover a broad range of therapeutic applications in several disciplines, including radiography, cardiac electrophysiology, interventional cardiology, and vascular surgery.
Expanding Clinical Applications and Market Reach
The Morph DNA Steerable Introducer family is expected to enhance several advanced medical procedures, including peripheral vascular intervention, renal denervation, endovascular aortic repair, carotid artery stenting, and atrial fibrillation mapping and ablation.
BioCardia’s earlier Morph product, limited to a single diameter, has already been employed in approximately 12,000 procedures across these applications. The new, more advanced product line aims to expand its reach to an even broader range of clinical practices, providing value to both physicians and patients.
Market Potential and Product Features
BioCardia estimates that over a million procedures conducted annually in the United States could benefit from these newly approved products, which are expected to be priced at a starting list price of $1,000.
Initially developed to meet the company’s own needs in cell therapy procedures, the Morph DNA steerable introducer family features innovative design elements, such as bidirectional steering, enhanced torque response, ergonomic actuation, and an adjustable brake for fine control. These features are poised to address common challenges and improve procedural outcomes in various cardiovascular and vascular interventions.
